interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Risperidone

Generic competition · all medicines · read 12 November 2026

Is there a generic of Risperidone, and who makes it?

Risperidone appears in 7 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 23 generic makers listed as marketed across them. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 5.9 and 20.1 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Risperidone7 dosage-form groups in the Orange Book
23generic makers listed
  1. Risperidone appears in 7 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 23 generic makers listed as marketed across them.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 5.9 and 20.1 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Four or more generic makers listed

Brand listed as marketed: Risperdal. 12 generic makers with 72 generic products listed as marketed; the first generic approval is dated 30 June 2008.

199019952000200520102015202020252030012brand 1993Rising Pharma Holdings Inc, first approval 8 October 2008Novitium Pharma Llc, first approval 9 October 2008Zydus Pharmaceuticals Usa Inc, first approval 16 October 2008Dr Reddys Laboratories Ltd, first approval 24 October 2008Torrent Pharmaceuticals Ltd, first approval 30 October 2008Renata Plc, first approval 29 December 2008Jubilant Cadista Pharmaceuticals Inc, first approval 23 March 2009Sandoz Inc, first approval 16 October 2009Chartwell Molecular Holdings Llc, first approval 18 May 2011Ajanta Pharma Ltd, first approval 24 August 2011Prinston Pharmaceutical Inc, first approval 29 November 2011Ipca Laboratories Ltd, first approval 26 June 2024data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Rising Pharma Holdings Inc8 October 20086
Novitium Pharma Llc9 October 20086
Zydus Pharmaceuticals Usa Inc16 October 20086
Dr Reddys Laboratories Ltd24 October 20086
Torrent Pharmaceuticals Ltd30 October 20086
Renata Plc29 December 20086
Jubilant Cadista Pharmaceuticals Inc23 March 20096
Sandoz Inc16 October 20096
Chartwell Molecular Holdings Llc18 May 20116
Ajanta Pharma Ltd24 August 20116
Prinston Pharmaceutical Inc29 November 20116
Ipca Laboratories Ltd26 June 20246

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Tablet, Orally Disintegrating, Oral

Four or more generic makers listed

Every brand product here is listed as discontinued. 6 generic makers with 29 generic products listed as marketed; the first generic approval is dated 24 February 2009.

200020052010201520202025203006brand 2003Pharmazone, first approval 24 February 2009Ph Health Ltd, first approval 30 April 2009Zydus Pharmaceuticals Usa Inc, first approval 1 May 2009Sandoz Inc, first approval 22 December 2009Sun Pharmaceutical Industries Ltd, first approval 6 August 2010Jubilant Generics Ltd, first approval 4 November 2011data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Pharmazone24 February 20096
Ph Health Ltd30 April 20096
Zydus Pharmaceuticals Usa Inc1 May 20092
Sandoz Inc22 December 20095
Sun Pharmaceutical Industries Ltd6 August 20105
Jubilant Generics Ltd4 November 20115

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Powder, Intramuscular

One to three generic makers listed

Brand listed as marketed: Risperdal Consta. 3 generic makers with 11 generic products listed as marketed; the first generic approval is dated 5 December 2023.

200020052010201520202025203003brand 2003Teva Pharmaceuticals Usa Inc, first approval 5 December 2023Amneal Eu Ltd, first approval 2 September 2025Nanomi Bv, first approval 2 September 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Teva Pharmaceuticals Usa Inc5 December 20234
Amneal Eu Ltd2 September 20254
Nanomi Bv2 September 20253

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Oral

Four or more generic makers listed

Brand listed as marketed: Risperdal. 6 generic makers with 6 generic products listed as marketed; the first generic approval is dated 30 January 2009.

1995200020052010201520202025203006brand 1996Ani Pharmaceuticals Inc, first approval 30 January 2009Pharmazone, first approval 29 July 2009Aurobindo Pharma Ltd, first approval 4 September 2009Amneal Pharmaceuticals, first approval 25 May 2011Tris Pharma Inc, first approval 12 December 2012Chartwell Molecular Holdings Llc, first approval 12 January 2015data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Ani Pharmaceuticals Inc30 January 20091
Pharmazone29 July 20091
Aurobindo Pharma Ltd4 September 20091
Amneal Pharmaceuticals25 May 20111
Tris Pharma Inc12 December 20121
Chartwell Molecular Holdings Llc12 January 20151

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Suspension, Extended Release, Subcutaneous

Brand listed, no generic listed as marketed

Brand listed as marketed: Uzedy. No generic is listed as marketed.

20202025203020352040204501brand 2023data datePatent 8221778 listed to expire 12 November 2027Patent 8741327 listed to expire 12 November 2027Patent 9023897 listed to expire 5 April 2033Patent 12128132 listed to expire 11 September 2040Patent 12383493 listed to expire 11 September 2040Patent 12329851 listed to expire 17 March 2042
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 12 November 2027Patent 8221778 drug product
  • 12 November 2027Patent 8741327 drug product
  • 5 April 2033Patent 9023897 drug product
  • 11 September 2040Patent 12128132 drug product
  • 11 September 2040Patent 12383493 drug product
  • 17 March 2042Patent 12329851

For Suspension, Extended Release, Intramuscular

Brand listed, no generic listed as marketed

Brand listed as marketed: Rykindo. No generic is listed as marketed.

202020252030203501brand 2023data datePatent 10406161 listed to expire 10 April 2032Patent 10098882 listed to expire 10 April 2032Patent 9532991 listed to expire 10 April 2032Patent 9446135 listed to expire 10 April 2032Patent 11110094 listed to expire 10 April 2032
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 10 April 2032Patent 10406161 drug product
  • 10 April 2032Patent 10098882 drug product
  • 10 April 2032Patent 9532991 drug product
  • 10 April 2032Patent 9446135 drug product
  • 10 April 2032Patent 11110094 drug product

For Suspension, Extended Release, Subcutaneous

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

201520202025203001brand 2018data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.